MiMedx Valuation
| MDXG Stock | USD 6.42 0.30 4.46% |
At this time, the firm appears to be undervalued. MiMedx Group secures a last-minute Real Value of $7.84 per share. The latest price of the firm is $6.42. Our model forecasts the value of MiMedx Group from analyzing the firm fundamentals such as return on equity of 0.22, and Profit Margin of 0.11 % as well as examining its technical indicators and probability of bankruptcy.
Price Book 4.9531 | Enterprise Value 847.2 M | Enterprise Value Ebitda 13.6413 | Price Sales 2.691 | Forward PE 19.5313 |
Undervalued
Today
Please note that MiMedx's price fluctuation is somewhat reliable at this time. Calculation of the real value of MiMedx Group is based on 3 months time horizon. Increasing MiMedx's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the MiMedx stock is determined by what a typical buyer is willing to pay for full or partial control of MiMedx Group. Since MiMedx is currently traded on the exchange, buyers and sellers on that exchange determine the market value of MiMedx Stock. However, MiMedx's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.42 | Real 7.84 | Target 12.0 | Hype 6.42 | Naive 6.15 |
The real value of MiMedx Stock, also known as its intrinsic value, is the underlying worth of MiMedx Group Company, which is reflected in its stock price. It is based on MiMedx's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of MiMedx's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of MiMedx Group helps investors to forecast how MiMedx stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of MiMedx more accurately as focusing exclusively on MiMedx's fundamentals will not take into account other important factors: MiMedx Total Value Analysis
MiMedx Group is now anticipated to have valuation of 847.18 M with market capitalization of 948.25 M, debt of 18.83 M, and cash on hands of 72.5 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the MiMedx fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
847.18 M | 948.25 M | 18.83 M | 72.5 M |
MiMedx Investor Information
About 70.0% of the company shares are owned by institutional investors. The book value of MiMedx was now reported as 1.37. The company has Price/Earnings To Growth (PEG) ratio of 2.97. MiMedx Group had not issued any dividends in recent years. The entity had 3235:10000 split on the 2nd of April 2008. Based on the key measurements obtained from MiMedx's financial statements, MiMedx Group is not in a good financial situation at this time. It has a very high odds of going through financial crisis in August.MiMedx Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. MiMedx has an asset utilization ratio of 132.19 percent. This implies that the Company is making $1.32 for each dollar of assets. An increasing asset utilization means that MiMedx Group is more efficient with each dollar of assets it utilizes for everyday operations.MiMedx Ownership Allocation
MiMedx Group maintains a total of 147.7 Million outstanding shares. The majority of MiMedx outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in MiMedx Group to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in MiMedx Group. Please pay attention to any change in the institutional holdings of MiMedx as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.MiMedx Profitability Analysis
The company reported the previous year's revenue of 348.88 M. Net Income was 42 M with profit before overhead, payroll, taxes, and interest of 288.73 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates MiMedx's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in MiMedx and how it compares across the competition.
About MiMedx Valuation
The stock valuation mechanism determines MiMedx's current worth on a weekly basis. Our valuation model uses a comparative analysis of MiMedx. We calculate exposure to MiMedx's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of MiMedx's related companies.MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. Mimedx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 811 people.
MiMedx Growth Indicators
Investing in growth stocks can be very risky. If the company such as MiMedx does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 149 M | |
| Quarterly Earnings Growth Y O Y | -0.222 | |
| Forward Price Earnings | 19.5313 |
Complementary Tools for MiMedx Stock analysis
When running MiMedx's price analysis, check to measure MiMedx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MiMedx is operating at the current time. Most of MiMedx's value examination focuses on studying past and present price action to predict the probability of MiMedx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MiMedx's price. Additionally, you may evaluate how the addition of MiMedx to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |